Skip to main content

Table 1 Characteristics of study population, by use of pegfilgrasim prophylaxis in cycle 1

From: Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

  Commercial Medicare
No Pegfilgrastim Use Pegfilgrastim Use No Pegfilgrastim Use Pegfilgrastim Use
(n = 16,512) (n = 34,266) (n = 20,195) (n = 50,842)
Patient
 Age (years)
  Mean (SD) 54.3 (10.2) 56.2 (10.9) 72.3 (5.4) 73.6 (5.9)
 Female, N (%) 14,623 (89%) 29,995 (88%) 16,604 (82%) 37,811 (74%)
 Chronic Comorbidities, N (%)
  Cardiovascular Disease 1403 (8%) 3851 (11%) 6124 (30%) 16,979 (33%)
  Diabetes 1750 (11%) 4211 (12%) 5217 (26%) 13,022 (26%)
  Liver Disease 621 (4%) 1386 (4%) 731 (4%) 1999 (4%)
  Lung Disease 1290 (8%) 3157 (9%) 3033 (15%) 8053 (16%)
  Renal Disease 311 (2%) 855 (2%) 1523 (8%) 4598 (9%)
  Osteoarthritis 1382 (8%) 3361 (10%) 4534 (22%) 11,620 (23%)
  Rheumatoid Disease 236 (1%) 561 (2%) 670 (3%) 1798 (4%)
  Thyroid Disorder 2105 (13%) 4569 (13%) 4470 (22%) 11,723 (23%)
 Body Weight and Nutritional Status, N (%)
  Obese 1244 (8%) 2688 (8%) 1715 (8%) 3959 (8%)
  Malnutrition 71 (0%) 289 (1%) 414 (2%) 1517 (3%)
 Proxies for Health Status, N (%)
  Hospice Care 38 (0%) 120 (0%) 572 (3%) 2037 (4%)
  SNF 100 (1%) 244 (1%) 926 (5%) 2194 (4%)
  Hospice or SNF 136 (1%) 352 (1%) 1400 (7%) 3962 (8%)
 Proxies for Physical Function, N (%)
  Use of Hospital Bed 26 (0%) 78 (0%) 162 (1%) 476 (1%)
  Use of Supplemental Oxygen 259 (2%) 681 (2%) 810 (4%) 2285 (4%)
  Use of Walking Aid 192 (1%) 506 (1%) 772 (4%) 2455 (5%)
  Use of Wheel Chair 53 (0%) 136 (0%) 378 (2%) 997 (2%)
  Any of Above 487 (3%) 1256 (4%) 1807 (9%) 5268 (10%)
 Use of Immunosuppressive Drugs, N (%) 5273 (32%) 11,113 (32%) 6612 (33%) 17,145 (34%)
 Other Conditions/Events Prior to Chemotherapy, N (%)
  Anemia 1896 (11%) 4721 (14%) 6025 (30%) 17,970 (35%)
  Neutropenia 290 (2%) 1295 (4%) 948 (5%) 4738 (9%)
  Infection 7902 (48%) 17,204 (50%) 11,545 (57%) 29,868 (59%)
  Recent Surgery (prior 90 days) 13,881 (84%) 28,100 (82%) 13,024 (64%) 30,427 (60%)
  History of Hospitalization for Any Reason 4549 (28%) 9985 (29%) 7739 (38%) 20,374 (40%)
  History of Chemotherapy 866 (5%) 2127 (6%) 1623 (8%) 4755 (9%)
  History of Radiation Therapy 910 (6%) 1955 (6%) 883 (4%) 2140 (4%)
Cancer and Chemotherapy, N (%)
 Breast Cancer 13,261 (80%) 26,622 (78%) 13,305 (66%) 25,675 (50%)
  TAC 389 (2%) 4179 (12%) 235 (1%) 1857 (4%)
  TC 8793 (53%) 14,918 (44%) 8032 (40%) 19,493 (38%)
  TCH 4079 (25%) 7525 (22%) 5038 (25%) 4325 (9%)
 NHL — CHOP±R 3251 (20%) 7644 (22%) 6890 (34%) 25,167 (50%)
 Year of Chemotherapy (Commercial), N (%)
  2010–2011 7150 (43%) 13,308 (39%)
  2012–2013 6108 (37%) 13,108 (38%)
  2014–2015 3254 (20%) 7850 (23%)
 Year of Chemotherapy (Medicare), N (%)
  2007–2009 6268 (31%) 12,984 (26%)
  2010–2012 8615 (43%) 21,004 (41%)
  2013–2015 5312 (26%) 16,854 (33%)
  1. TAC docetaxel + doxorubicin + cyclophosphamide, TC docetaxel + cyclophosphamide, TCH docetaxel + cyclophosphamide + trastuzumab, CHOP cyclophosphamide + doxorubicin + vincristine + prednisone with rituximab (R)